For Purchasers and Clinical Engineers
For Patients and Consumers
Automated external defibrillators (AEDs) are portable, life-saving devices designed to treat people experiencing sudden cardiac arrest, a medical condition in which the heart stops beating suddenly and unexpectedly.
The combination of CPR and early defibrillation is effective in saving lives when used in the first few minutes following collapse from sudden cardiac arrest.
On this page
- What Are AEDs?
- Check Your AED: Is it FDA Approved?
- FDA-Approved AEDs
- Important Information for AED Manufacturers
- The FDA's Continued Efforts to Keep AEDs Reliable
AEDs are portable, life-saving devices designed to treat people experiencing sudden cardiac arrest, a medical condition in which the heart suddenly and unexpectedly stops beating. The AED system includes accessories, such as a battery and pad electrodes, that are necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock. There are two main types of AEDs: public access and professional use.
- Public access AEDs can be found in airports, community centers, schools, government buildings, hospitals, and other public locations. They are intended to be used by laypeople who have received minimal training.
- Professional use AEDs are used by first responders, such as emergency medical technicians (EMTs) and paramedics, who receive additional AED training.
AEDs can be semi-automated or fully automated.
- Semi-automated defibrillators analyze the heart's rhythm, and if an abnormal heart rhythm is detected that requires a shock, then the device prompts the user to press a button to deliver a defibrillation shock.
- Fully automated defibrillators analyze the heart's rhythm and deliver a defibrillation shock if commanded by the device software without user intervention.
The FDA published a final order in February 2015 requiring premarket approval (PMA) applications for new and existing AEDs and necessary AED accessories. According to the final order, manufacturers of all necessary AED accessories, such as batteries, pad electrodes, adapters and hardware keys for pediatric use, must file a premarket approval application (PMA) within 90 days of the date of the final order; however, the FDA did not intend to enforce compliance with the PMA submission requirement for these necessary AED accessories for 60 months following the date of the final order, which was February 3, 2020. In response to feedback from stakeholders, the FDA stated it did not intend to enforce the PMA submission requirement for the necessary AED accessories until February 3, 2021. The FDA has since issued a guidance to revise its compliance policy regarding the deadline for filing PMAs for these necessary AED accessories, announcing that the FDA does not intend to enforce compliance with the PMA submission requirement for these necessary accessories until February 3, 2022. This revised compliance policy allows facilities additional time, particularly during the COVID-19 pandemic, to procure FDA-approved AEDs and manufacturers to file the required PMA for necessary accessories, respectively.
There are now FDA-approved AEDs available, and we encourage you to ensure your AED is FDA-approved; if it is not, we encourage you to begin making plans to transition to an FDA-approved AED.
If you or your organization own(s) an AED system, the FDA recommends you:
- Check the table below to see if your AED is FDA-approved. Contact the manufacturer of your AED if you are not sure if your AED is FDA-approved.
- Contact the manufacturer of your AED if your AED is not FDA-approved and you have not received a letter about your AED.
- Be aware that if your AED is not FDA-approved, compatible necessary AED accessories may no longer be available to support your AED after February 3, 2022.
- Contact the manufacturer of your AED or AED accessories for information specific to your product.
- Given the importance of these devices in emergency situations, the FDA recommends you continue to keep your AED available for use until you receive an FDA- approved AED.
- Report problems with AEDs to the FDA by submitting a voluntary report online at MedWatch.
The table below lists all AEDs that have received premarket approval from the FDA. If your AED is listed below, no matter your purchase date, the AED is considered FDA-approved. The FDA will update this table when new AEDs are approved. For descriptions of these devices, their indications for use, and related information, follow the Premarket Database links.
Important: If your AED is not listed in this table, please contact the manufacturer of your AED for more information about your device.
|Manufacturer||Device Name||Approval Date||Premarket Database|
|Cardiac Science Corporation||Powerheart G3 AED||12/07/2018||P160033|
|Cardiac Science Corporation||Powerheart G3 Plus AED||12/07/2018||P160033|
|Cardiac Science Corporation||Powerheart G5 AED||12/07/2018||P160033|
|Cardiac Science Corporation||Powerheart G3 PRO AED||12/06/2018||P160034|
|Defibtech, LLC||Lifeline/ReviveR DDU-100||02/01/2018||P160032|
|Defibtech, LLC||Lifeline/ReviveR AUTO DDU-120||02/01/2018||P160032|
|Defibtech, LLC||Lifeline/ReviveR VIEW DDU-2300||02/01/2018||P160032|
|Defibtech, LLC||Lifeline/ReviveR VIEW AUTO DDU-2200||02/01/2018||P160032|
|Defibtech, LLC||Lifeline/ReviveR ECG DDU-2450||02/01/2018||P160032|
|Defibtech, LLC||Lifeline/ReviveR ECG+ DDU-2475||02/01/2018||P160032|
|HeartSine Technologies, LLC||SAM 350P (Samaritan Public Access Automated External Defibrillator)||01/12/2017||P160008|
|HeartSine Technologies, LLC||SAM 360P (Samaritan Public Access Automated External Defibrillator)||01/12/2017||P160008|
|HeartSine Technologies, LLC||SAM 450P (Samaritan Public Access Automated External Defibrillator)||01/12/2017||P160008|
|Philips Medical Systems||HeartStart Home||06/06/2019||P160029|
|Philips Medical Systems||HeartStart OnSite||06/06/2019||P160029|
|Philips Medical Systems||HeartStart FR3||05/11/2020||P160028|
|Philips Medical Systems||HeartStart FRx||05/11/2020||P180028|
|Physio-Control, Inc.||LIFEPAK CR Plus Defibrillator||12/21/2017||P160012|
|Physio-Control, Inc.||LIFEPAK EXPRESS Defibrillator||12/21/2017||P160012|
|Physio-Control, Inc.||LIFEPAK CR2 Defibrillator||12/21/2018||P170018|
|Physio-Control, Inc.||LIFEPAK 15 Monitor/Defibrillator||07/02/2018||P160026|
|Physio-Control, Inc.||LIFEPAK 20E Defibrillator/ Monitor||07/02/2018||P160026|
|Physio-Control, Inc.||LIFEPAK 1000 Defibrillator||07/02/2018||P160026|
|ZOLL Medical Corporation||AED Plus and Fully Automatic AED Plus||05/26/2017||P160015|
|ZOLL Medical Corporation||X Series Defibrillator||12/27/2017||P160022|
|ZOLL Medical Corporation||R Series Defibrillator||12/27/2017||P160022|
|ZOLL Medical Corporation||AED Pro Defibrillator||12/27/2017||P160022|
|ZOLL Medical Corporation||AED 3 BLS Defibrillator||12/27/2017||P160022|
|ZOLL Medical Corporation||Propaq MD Defibrillator||12/27/2017||P160022|
To ensure the quality and reliability of AEDs the FDA now requires manufacturers to obtain premarket approval for all AEDs.
Manufacturers of currently legally marketed necessary AED accessories, such as batteries, pad electrodes, adapters and hardware keys for pediatric use, were required to file a premarket approval application (PMA) by February 3, 2020.
FDA does not intend to enforce compliance with the February 3, 2020, deadline for necessary AED accessories until February 3, 2022 to allow health care facilities time to transition to FDA-approved AEDs. Therefore, if a PMA is not filed by February 3, 2022, the manufacturer must cease marketing their accessories. This marketing deadline includes necessary AED accessories that are labeled for AEDs that are not FDA-approved.
FDA expects that necessary AED accessories will be labeled for use with an FDA-approved AED device (on the list above). Manufacturers submitting a PMA for necessary AED accessories should be aware that they can continue to market those accessories while the PMA is pending until the FDA issues a decision (approval, not approvable, or denial decision). After a PMA decision is made, only FDA-approved accessories can continue to be marketed.
The FDA's premarket approval of new and existing AEDs is based on a determination that the application contains sufficient valid scientific evidence to reasonably assure the device is safe and effective for its intended use. This regulatory pathway requires manufacturers to receive FDA approval before initiating design, manufacturing, or labeling changes to the device, and imposes certain other annual reporting requirements.
Once the AEDs are on the market, the FDA proactively monitors the safety and reliability of AEDs by reviewing the AED manufacturers' manufacturing and design changes, performance reports, and medical device reports (MDRs). When a company initiates a correction or removal action, the FDA posts information about the action in the Medical Device Recall Database. For information on AED systems or necessary AED accessories that have been recalled, you can search the database using the device's product code. Once classified, the FDA monitors the recall to ensure that the recall strategy has been effective.
The FDA recognizes the importance of AEDs as life-saving devices. Problems associated with many AEDs include design and manufacturing issues, such as inadequate control of components purchased from suppliers or inadequate validation of manufacturing processes. When this occurs, an AED device can malfunction and may contribute to patient harm or prevent the rescue of the patient.
Given this, the FDA has taken several actions to assure that current and future AED devices and necessary accessories are safe and reliable. These actions include:
- By February 3, 2022: Manufacturers of previously-cleared necessary accessories (such as batteries, pad electrodes, adapters) for the operation of AED systems that are FDA-approved are required to file a premarket approval application (PMA).
- October 27, 2020: FDA revised its compliance policy regarding the deadline for filing a PMA for previously-cleared necessary AED accessories until February 3, 2022. This revised compliance policy allows health care facilities and manufacturers to remain focused on public health needs related to the COVID-19 public health emergency, while allowing time to transition to FDA-approved AEDs.
- By February 3, 2020: Original date manufacturers of previously-cleared necessary accessories (such as batteries, pad electrodes, adapters) for AED systems that are FDA-approved were to file a PMA.
- April 2019: The FDA sent letters to all AED manufacturers, who did not submit a PMA for their AEDs as required by the final order, reminding them they can no longer market their AED; the letters also informed the manufactures that necessary AED accessories may not be marketed after February 3, 2020, if a PMA is not filed. Manufacturers were asked to provide a plan for these AEDs and necessary AED accessories, including a timeline for servicing and phase-out activities, a plan for communicating with their customers, and an estimate of the volume of AEDs and accessories that remain in the field.
- November 1, 2017: The FDA and Philips Medical Systems LLC entered a consent decree of permanent injunction prohibiting Philips Medical Systems, Philips Healthcare, and those individually named from manufacturing, processing, packing, holding, or distributing AEDs from two facilities until they comply with the Federal Food, Drug, and Cosmetic Act (FD&C Act).
- February 2015: The FDA published a final order in February 2015 requiring premarket approval (PMA) applications for new and existing AEDs and necessary AED accessories.
- December 2013: The FDA issued a Safety Communication alerting all users of the Philips HeartStart FRx, HS1 Home and HS1 OnSite AEDs manufactured between 2005 and 2012 that these devices may fail to deliver a shock in the event of an emergency.
- March 2013: The FDA published a proposed order to allow for notice and comment regarding the FDA's recommendation to require premarket approval (PMA) applications for AEDs and necessary AED accessories.
- January 2011: The FDA convened a public meeting of the Circulatory System Device Panel of the Medical Devices Advisory Committee where the FDA presented its comprehensive assessment of AEDs. The panel of independent experts considered the FDA's assessment of AEDs and its recommendation that more stringent FDA oversight be applied to reduce future AED problems. The panel agreed with the FDA's recommendation to require PMA applications for AEDs.
- November 2010: The FDA released the External Defibrillator Improvement Initiative Paper to foster the development of better-performing external defibrillators and to address the current industry practices for designing and manufacturing devices and identifying, reporting, and taking action to address device complaints they receive.